A detailed history of Hantz Financial Services, Inc. transactions in Genmab A/S stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 321 shares of GMAB stock, worth $6,525. This represents 0.0% of its overall portfolio holdings.

Number of Shares
321
Holding current value
$6,525
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$18.69 - $24.14 $5,999 - $7,748
321 New
321 $6,000
Q2 2020

Aug 06, 2024

BUY
$20.05 - $33.89 $220 - $372
11 New
11 $0

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.4B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.